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Letter to the editor 
 
Development of efficacious immunotherapy approaches in glioblastoma remains 
challenging. The induction of anti-glioma immune responses utilizing various 
oncolytic virus strains has been reported from pre-clinical and early phase clinical 
trials.1 The optimal design for efficacy studies of oncolytic virotherapy in 
glioblastoma patients is under debate, but likely such studies will preferentially be 
performed in patients with recurrent glioblastoma.  
In clinical practice, this group of patients is often treated with the anti-angiogenic 
vascular endothelial growth factor A (VEGF)-neutralizing antibody bevacizumab for 
its capacity to improve and maintain quality of life, mainly through anti-edematous 
effects. Beyond promoting angiogenesis, VEGF exerts immunosuppressive effects,2 
which are thought to be potentially relevant in the context of immunotherapy in 
glioblastoma. For example, in the Re-ACT trial, median overall survival of patients 
with recurrent glioblastoma was prolonged by 3.2 months upon addition of a tumor-
specific vaccine to bevacizumab (hazard ratio = 0.47, p=0.021) and benefit was 
associated with vaccine-induced titers within the experimental arm,3 but in the ACT-
IV trial the same vaccine had no effect on outcome as an add-on to standard 
chemoirradiation in patients with newly diagnosed glioblastoma irrespective of titer 
generation in response to vaccination.4  
This led us to explore whether bevacizumab should be incorporated into virotherapy 
clinical trial designs in glioblastoma. We employed a non-immunogenic genetic 
model of IDH wildtype glioblastoma which is histologically, immunologically and 
molecularly highly similar to its human counterpart (N/tv-a;Cdkn2a-/-
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;Ptenfl/fl:PDGF,Cre).5 Animal research was prospectively approved by the 
Institutional Animal Care and Use Committee of the Fred Hutchinson Cancer 
Research Center, Seattle, WA (Animal assurance institutional #A3226-01; Protocol 
#50842). Mouse glioblastomas were treated with oHSVULBP3, an oncolytic herpes 
simplex virus 1 strain that was armed with a ULBP3 gene expression cassette to boost 
anti-cancer immunity (Figure 1A).5 There was a twofold increase in VEGF protein 
levels upon treatment with oHSVULBP3 versus PBS in protein lysates from 5 mouse 
glioblastomas per group (Figure 1B). A major proportion of VEGF is, however, 
immobilized in the extracellular matrix. In order to exert its effects, immobilized 
VEGF isoforms need to be cleaved by matrix metalloproteinases (MMP), 
predominantly MMP3 and MMP9.6 Although there was an about threefold increase in 
MMP9 protein levels upon treatment with oHSVULBP3, our model reflects a scenario 
of overall low MMP expression (Figure 1B). In order to model effects of MMP 
expression on the efficacy of oHSVULBP3, we designed an oHSV vector containing an 
MMP9 expression cassette in addition to the ULBP3 cassette, yielding MMP9 
expression specifically in the small virus-infected foci of the tumor. The survival 
benefit of tumor-bearing mice obtained with oHSVULBP3 versus PBS (HR 0.27, 
p<0.001) was nearly abolished in mice randomized to intratumoral injection with 
oHSVULBP3-MMP9 (HR=0.56, p=0.039, Figure 1C). Co-treatment of mice with the 
murine VEGF neutralizing antibody B20 and intracranial injections of PBS, 
oHSVULBP3 or oHSVULBP3-MMP9 indicated that VEGF was a major driver of reduced 
therapeutic efficacy of oHSVULBP3 in the presence of MMP9. Consistent with clinical 
trials of anti-VEGF treatment in glioblastoma patients, there was no effect of B20 on 
mouse survival (HR 0.86, p=0.71), but combining oHSVULBP3-MMP9 with B20 resulted 
in a marked survival benefit compared to oHSVULBP3-MMP9 alone (HR = 0.32, log rank 
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p=0.027, Figure 1D). By contrast, no effect of B20 was observed upon treatment with 
oHSVULBP3 lacking the MMP-9 expression cassette (HR 1.11, p=0.83, data not 
shown). In line with the notion of an immunosuppressive effect of MMP9 and 
subsequent VEGF release, nCounter geneset analysis revealed down-regulation of the 
genesets toll-like receptor (TLR) signaling (p<0.001) and T-cell activation and 
checkpoint signaling (p=0.001) in tumors treated with oHSVULBP3-MMP9 versus 
oHSVULBP3 (Figure 1E,F), indicating inhibitory effects on both the myeloid and 
lymphocytic compartment. Interestingly, disruption of autocrine VEGF signaling in 
tumor cells results in loss of MMP9 expression, consistent with a positive feedback 
loop between VEGF and MMP9.7 
In summary our data suggest a mechanism of resistance to virotherapy that involves 
VEGF release from the extracellular matrix by MMP9 and support a clinical trial 
design that incorporates the combination of virotherapy and bevacizumab. The 
unfavorable effect of MMP9 on the efficacy of virotherapy argues against oncolytic 
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Figure 1. Anti-VEGF counteracts MMP9-mediated resistance to virotherapy. 
A. Experimental setup. B. Proteomics analysis (R&D ARY028) of pooled tumor 
lysates (N=5 per group) from N/tv-a;Cdkn2a-/-;Ptenfl/fl:PDGF,Cre glioblastomas 
treated by intracranial injection of PBS or oHSVULBP3 as indicated. C. Symptom-free 
survival. PBS, N=20; oHSVULBP3, N=20; oHSVULBP3-MMP9, N=12. Kaplan-Meier 
curves were compared utilizing the log rank test. D. Symptom free survival. PBS 
alone N=7, co-treatment with B20 (anti-VEGF; N=7, 5 mg/kg i.v. every other day), or 
upon intratumoral injection with oHSVULBP3-MMP9 (1x106 PFU) alone (N=5) or in 
combination with B20 (N=5). Kaplan-Meier curves were compared utilizing the log 
rank test. E. Volcano plot of differentially down-regulated genes analyzed by 
nCounter analysis of the myeloid innate immunity geneset after treatment with 
oHSVULBP3 or oHSVULBP3-MMP9. F. Gene set enrichment analysis of genes down-
regulated upon injection with oHSVULBP3-MMP9 versus oHSVULBP3 (orange in panel E). 
 

